ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan Sells 5,140 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan sold 5,140 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.90, for a total value of $92,006.00. Following the completion of the transaction, the chief operating officer now owns 36,340 shares of the company’s stock, valued at $650,486. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Brendan Teehan also recently made the following trade(s):

• On Monday, February 26th, Brendan Teehan sold 624 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $24.67, for a total value of $15,394.08.
• On Monday, January 8th, Brendan Teehan sold 731 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $21,900.76.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD opened at $18.20 on Thursday. ACADIA Pharmaceuticals Inc. has a 12-month low of $17.56 and a 12-month high of $33.99. The company has a fifty day simple moving average of $23.85 and a 200 day simple moving average of $24.48.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). The business had revenue of $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The firm’s revenue for the quarter was up 69.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. On average, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.64 earnings per share for the current year.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in ACADIA Pharmaceuticals by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,925,641 shares of the biopharmaceutical company’s stock worth $211,463,000 after acquiring an additional 525,048 shares during the last quarter. RTW Investments LP lifted its stake in shares of ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock valued at $241,255,000 after purchasing an additional 1,793,288 shares during the period. BlackRock Inc. raised its stake in ACADIA Pharmaceuticals by 1.7% during the second quarter. BlackRock Inc. now owns 10,039,501 shares of the biopharmaceutical company’s stock valued at $240,446,000 after buying an additional 170,370 shares during the last quarter. State Street Corp raised its stake in ACADIA Pharmaceuticals by 2.8% during the third quarter. State Street Corp now owns 6,778,871 shares of the biopharmaceutical company’s stock valued at $110,902,000 after buying an additional 184,921 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of ACADIA Pharmaceuticals by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,550,906 shares of the biopharmaceutical company’s stock worth $85,649,000 after purchasing an additional 271,652 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ACAD shares. Robert W. Baird began coverage on ACADIA Pharmaceuticals in a research report on Tuesday, January 30th. They set an “outperform” rating and a $40.00 price target on the stock. Mizuho downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $39.00 to $25.00 in a research note on Tuesday, March 12th. JMP Securities reiterated a “market outperform” rating and issued a $42.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Oppenheimer reaffirmed a “market perform” rating and issued a $25.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, February 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $42.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.12.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.